Late-stage pharmaceutical R&D and pricing policies under two-stage regulation
Year of publication: |
December 2016
|
---|---|
Authors: | Jobjörnsson, Sebastian ; Forster, Martin ; Pertile, Paolo ; Burman, Carl-Fredrik |
Published in: |
Journal of health economics. - Amsterdam [u.a.] : Elsevier, ISSN 0167-6296, ZDB-ID 625797-5. - Vol. 50.2016, p. 298-311
|
Subject: | Pharmaceutical pricing and reimbursement | Rare diseases | Optimal sample size | Static and dynamic efficiency | Cost-effectiveness threshold | Arzneimittel | Pharmaceuticals | Theorie | Theory | Pharmaindustrie | Pharmaceutical industry | Preisregulierung | Price regulation | Regulierung | Regulation | Arzneimittelmarkt | Pharmaceutical market | Effizienz | Efficiency | Gesundheitskosten | Health care costs |
-
Late-stage pharmaceutical R & D and pricing policies under two-stage regulation
Jobjornsson, Sebastian, (2015)
-
The effects of price regulation on pharmaceutical expenditure and availability
Kortelainen, Mika, (2023)
-
Effects of pharmaceutical price regulation : China's evidence between 1997 and 2008
Wu, Binzhen, (2015)
- More ...
-
Late-stage pharmaceutical R & D and pricing policies under two-stage regulation
Jobjornsson, Sebastian, (2015)
-
Dynamic, economic approaches to HTA under uncertainty
Forster, Martin, (2011)
-
Optimal sequential sampling rules for the economic evaluation of health technologies
Pertile, Paolo, (2010)
- More ...